0QAV.LSE Nanobiotix
- Market cap
- EUR 614M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is 0QAV.LSE undervalued?
Graham numberThe Graham number of Nanobiotix cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nanobiotix fundamental analysis
No fundamental analysis for Nanobiotix yet.
Nanobiotix stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nanobiotix
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to de…
Full company profileNanobiotix financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nanobiotix annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.56M | 252K | 116K | 68.0K | 50.0K | 10.0K | 4.78M | 30.1M | -11.6M | 29.6M | 22.2M |
| Gross Profit | 1.12M | -93.6K | 3.48M | 2.54M | 2.33M | 2.65M | 3.28M | 42.4M | -7.19M | - | 22.2M |
| Operating Income | -25.6M | -28.7M | -33.4M | -49.2M | -38.9M | -49.8M | -50.5M | -26.8M | -72.7M | -13.8M | -79.3M |
| EBITDA | -25.0M | -28.9M | -32.2M | -46.8M | -34.9M | -47.3M | -53.8M | -34.0M | -61.6M | -12.2M | -76.2M |
| Net Income | -21.9M | -26.1M | -30.3M | -50.9M | -33.6M | -47.0M | -57.0M | -39.7M | -68.1M | -24.0M | -137M |
| EPS | -1.43 | -1.50 | -1.55 | -2.35 | -1.38 | -1.35 | -1.64 | -1.08 | -1.44 | -0.50 | -2.81 |
| Balance Sheet | |||||||||||
| Total Assets | 30.2M | 57.2M | 46.0M | 56.1M | 134M | 102M | 59.8M | 93.9M | 67.4M | 67.8M | 128M |
| Total Liabilities | 13.0M | 13.5M | 32.0M | 58.1M | 63.6M | 75.0M | 86.8M | 95.7M | 133M | 152M | 162M |
| Shareholders' Equity | 17.2M | 43.6M | 14.1M | -2.04M | 70.4M | 26.7M | -27.0M | -1.84M | -65.7M | -84.5M | -33.4M |
| Cash & Short-term Investments | 21.1M | 47.2M | 36.2M | 35.1M | 119M | 83.9M | 41.4M | 75.3M | 49.7M | 52.8M | 111M |
| Total Debt | 5.67M | 4.73M | 20.5M | 44.5M | 49.0M | 46.0M | 53.2M | 50.6M | 50.9M | 95.3M | 107M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -18.4M | -21.1M | -26.0M | -41.5M | -28.2M | -31.0M | -38.0M | -12.5M | -20.5M | -35.0M | -88.1M |
| Capital Expenditure | 400K | 1.46M | 506K | 1.44M | 107K | 233K | 93.0K | 328K | 846K | 538K | 2.51M |
| Free Cash Flow | -18.8M | -22.6M | -26.5M | -43.0M | -28.3M | -31.2M | -38.1M | -12.8M | -21.4M | -35.5M | -90.6M |
| Ratios | |||||||||||
| ROE | -127.5% | -59.9% | -215.7% | - | -47.7% | -176.1% | - | - | - | - | - |
| ROA | -72.5% | -45.7% | -65.9% | -90.8% | -25.1% | -46.2% | -95.4% | -42.3% | -101.1% | -35.4% | -106.9% |
| Net Profit Margin | -1,404.3% | -10,375.6% | -26,159.5% | -74,875.0% | -67,180.0% | -470,030.0% | -1,194.3% | -132.1% | - | -80.8% | -617.7% |
| Debt to Equity | 0.33x | 0.11x | 1.46x | - | 0.70x | 1.72x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Nanobiotix dividends
Nanobiotix has not paid dividends in the last 9 fiscal years.
Last stock split: 572:523 on Feb 25, 2014.
Who owns Nanobiotix
- Insiders 15.44%
- Institutions 31.04%
- Public & others 53.52%
- Shares outstanding 19.6M
- Free float 35.1M
Nanobiotix company profile
- Company name
- Nanobiotix
- Ticker
- 0QAV.LSE
- ISIN
- FR0011341205
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 98
- Fiscal year end
- December
- Address
- 60 rue de Wattignies, Paris, France, 75012
- Phone
- 33 1 40 26 04 70
- Website
- nanobiotix.com
About Nanobiotix
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Nanobiotix management
9- Dr. Laurent Levy Ph.D.Co-Founder, President of the Executive Board & CEO · born 1973
- Ms. Anne-Juliette Hermant M.A.Chief People Officer & Member of Executive Board · born 1974
- Dr. Louis Kayitalire M.D.Chief Medical Officer & Member of Executive Board · born 1959
- Mr. Earl J. Bergey Ph.d.Co-Founder · born 1955
- Mr. Arnd Christ MBACFO & Member of Executive Board · born 1966
- Mr. Brandon OwensVP of Strategic Marketing & Corporate Communication
- Ms. Margaret GalluzziVP & Global Head of Clinical Operations
- Dr. Leonard A. Farber M.D.Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board
- Ms. Anne-Sophie LariviereChief Product Innovation & Delivery Officer